# Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

> **NCT00955110** · PHASE4 · COMPLETED · sponsor: **Endo Pharmaceuticals** · enrollment: 78 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Oxymorphone ER
- **DRUG:** Oxycodone CR
- **DRUG:** Placebo
- **DRUG:** Hydromorphone

## Key facts

- **NCT ID:** NCT00955110
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00955110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00955110, "Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00955110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*